by According to Report, the Swine Vaccines Market size is expected to reach around US$ 6.5 billion by 2030 and is anticipated to grow at a CAGR of 5.9% during forecast period 2021 to 2030.
Get Sample Copy of This Report@ https://www.visionresearchreports.com/report/sample/39081
Increasing prevalence of diseases, a surge in the demand for animal protein, and growth in R&D expenditure for vaccines innovation are driving the market growth. Porcine Parvovirus (PPV), Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine circovirus type 2 (PCV2), Foot & Mouth Disease, Classical Swine Fever, and others remain to be extremely prevalent diseases in pig farms affecting economic losses.
Swine production is a key component of global food security, agricultural countries, and local & international business. Contagious diseases impact pig health and stability and productivity of the swine industry globally. Thus, the rising prevalence of diseases in swine is estimated to drive the market over the forecast years. Porcine Parvovirus (PPV) is a reproductive disease present in most pig farms globally. Porcine Reproductive and Respiratory Syndrome (PRRS) remains to be a highly prevalent disease in pig farms affecting economic losses through its adverse effects on reproduction and growth as well as by clinical illness.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 6.5 billion by 2030 |
| Growth Rate | CAGR of 5.9% From 2021 to 2030 |
| Largest Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Type |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Merck Animal Health; Ceva; Zoetis; BoehringerIngelheim GmbH; Elanco; Indian Immunologicals Ltd.; BiogénesisBagó; Phibro Animal Health; KM Biologics; HIPRA |
COVID-19 has compressed the global economy and with it the manufacturing and marketing sector, production, disruption, financial.
The significant drop in COVID-19 cases due to mass inoculations programs worldwide are anticipated to increase revenue flow in the global economy and contribute to the growth of the car electrical products market. The COVID-19 impact has changed the growth projections of many sectors and businesses. The analysts put their excellent and well-researched opinions in the report. The opinions will help the stakeholders to make their strategy accordingly.
Key Players
- Merck Animal Health
- Ceva
- Zoetis
- Boehringer Ingelheim GmbH
- Elanco
- Indian Immunologicals Ltd.
- BiogénesisBagó
- Phibro Animal Health
- KM Biologics
- HIPRA
Market Segmentation
- By Type
- Swine Influenza
- Classical Swine Fever
- Porcine Parvovirus
- Porcine Circovirus Type 2
- M.Hyo
- ActinobacillusPleuropneumonia
- PRRS
- Foot & Mouth Disease
- Pseudorabies
- PEDV
- Others
- By Product
- Attenuated Live Vaccines
- Inactivated Vaccines
- Subunit Vaccines
- DNA Vaccines
- Recombinant Vaccines
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- Saudi Arabia
- South Africa
- North America
Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/39081
Reasons to Purchase this Report:
– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Swine Vaccines Market, By Type
7.1. Swine Vaccines Market, by Type, 2021-2030
7.1.1. Swine Influenza
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Classical Swine Fever
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Porcine Parvovirus
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Porcine Circovirus Type 2
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. M.Hyo
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. ActinobacillusPleuropneumonia
7.1.6.1. Market Revenue and Forecast (2017-2030)
7.1.7. PRRS
7.1.7.1. Market Revenue and Forecast (2017-2030)
7.1.8. Foot & Mouth Disease
7.1.8.1. Market Revenue and Forecast (2017-2030)
7.1.9. Pseudorabies
7.1.9.1. Market Revenue and Forecast (2017-2030)
7.1.10. PEDV
7.1.10.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Swine Vaccines Market, By Product
8.1. Swine Vaccines Market, by Product, 2021-2030
8.1.1. Attenuated Live Vaccines
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Inactivated Vaccines
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Subunit Vaccines
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. DNA Vaccines
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Recombinant Vaccines
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Swine Vaccines Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Type (2017-2030)
9.1.2. Market Revenue and Forecast, by Product (2017-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.1.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.1.4.2. Market Revenue and Forecast, by Product (2017-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Type (2017-2030)
9.2.2. Market Revenue and Forecast, by Product (2017-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.2.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.2.4.2. Market Revenue and Forecast, by Product (2017-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
9.2.5.2. Market Revenue and Forecast, by Product (2017-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
9.2.6.2. Market Revenue and Forecast, by Product (2017-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.3.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.3.4.2. Market Revenue and Forecast, by Product (2017-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
9.3.5.2. Market Revenue and Forecast, by Product (2017-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
9.3.6.2. Market Revenue and Forecast, by Product (2017-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.4.2. Market Revenue and Forecast, by Product (2017-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.4.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.4.4.2. Market Revenue and Forecast, by Product (2017-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
9.4.5.2. Market Revenue and Forecast, by Product (2017-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
9.4.6.2. Market Revenue and Forecast, by Product (2017-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Type (2017-2030)
9.5.2. Market Revenue and Forecast, by Product (2017-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.5.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.5.4.2. Market Revenue and Forecast, by Product (2017-2030)
Chapter 10. Company Profiles
10.1. Merck Animal Health
10.1.1. Company Overview
10.1.2. Type Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Ceva
10.2.1. Company Overview
10.2.2. Type Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Zoetis
10.3.1. Company Overview
10.3.2. Type Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Boehringer Ingelheim GmbH
10.4.1. Company Overview
10.4.2. Type Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Elanco
10.5.1. Company Overview
10.5.2. Type Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Indian Immunologicals Ltd.
10.6.1. Company Overview
10.6.2. Type Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. BiogénesisBagó
10.7.1. Company Overview
10.7.2. Type Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Phibro Animal Health
10.8.1. Company Overview
10.8.2. Type Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. KM Biologics
10.9.1. Company Overview
10.9.2. Type Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. HIPRA
10.10.1. Company Overview
10.10.2. Type Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
Buy This Report, click here@ https://www.visionresearchreports.com/report/cart/39081
About Us: Our team of skilled and experienced analysts specializes in troubleshooting problems faced by our clients. For comprehensive summary of our services and market research requirements for Global industry.
Contact Us:
call: +1 9197 992 333
Vision Research Report
Any Assistance, Email – sales@visionresearchreports.com
